Skip to main content
Springer Nature Link
Log in

Ergoline and non-ergoline derivatives in the treatment of Parkinson’s disease

  • WORKSHOP 3
  • Published:
Journal of Neurology Aims and scope Submit manuscript

An Erratum to this article was published on 01 September 2008

Abstract

There are a large variety of dopamine agonists available. Especially de novo patients are treated with dopamine agonists to avoid dyskinesia. Dopamine agonists can be subdivided into ergoline and non-ergoline derivatives. This distinction raises the question whether there are differences in the effects to treat symptoms, not only in the side effects between the individual dopamine agonists but also between these two groups. Pergolide is now considered a second line drug because of its particularly high tendency towards valvular heart disease. Some authors claim that all ergoline-derivatives may cause this problem, while own results do not necessarily support this view. We recommend performing echocardiography on those patients being treated with an ergotderivative. New data support the view that all dopaminergic drugs may cause somnolence and that there is no preference for non-ergots. It may be that the number of gamblers is slightly higher among patients treated with pramipexole than in others. Dopamine agonists with a high affinity to D3 receptors have a good anti-anhedonic potency. In cell culture all dopamine agonists studied so far show neuroprotective properties in cell culture. The introduction of a slow-release formulation for ropinirole and the rotigotine and lisuride patches have opened new ways of continuous dopamine receptor stimulation. Taken together, dopamine agonists show individual properties and there are differences between ergot and non-ergot derivatives.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baseman DG, O’Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey Jr. RB (2004) Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63:301–304

    PubMed  CAS  Google Scholar 

  2. Dhawan V,Medcalf P, Stegie F, Jackson G, Basu S, Luce P,Odin P, Chaudhuri KR (2005) Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson’s disease patients treated with cabergoline. J Neural Transm 112:661–668

    Article  PubMed  CAS  Google Scholar 

  3. Eggert K, Odin P, Gasser T,Meinertz T, Strasser R, Osterspey A, Deuschl G, Oertel WH (2005) Fachgerechter Einsatz von Dopamin-Agonisten. Deutsches Ärzteblatt 102:B22–B23

    Google Scholar 

  4. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JH, Abbaszade I, Hollis JM, Largent BI, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75–81

    PubMed  CAS  Google Scholar 

  5. Flowers CM, Racoosin JA, Lu SL, Beitz JG (2003) The US Food and Drug Administration’s registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 78:730–731

    PubMed  Google Scholar 

  6. Frucht S, Rogers JD, Greene PE (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52:1908–1910

    PubMed  CAS  Google Scholar 

  7. Hanna PA, Ratkos L, Ondo WG, Jankovic J (2001) Switching from pergolide to pramipexole in patients with Parkinson’s disease. J Neural Transm 108:63–70

    Article  PubMed  CAS  Google Scholar 

  8. Horowski R, Jahnichen S, Pertz HH (2004) Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role. Mov Disord 19(12):1523–1524

    Article  PubMed  Google Scholar 

  9. Horvath J, Fross RD, Kleiner-Fisman G, Lerech R, Stadler H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19:656–662

    Article  PubMed  Google Scholar 

  10. Jahnichen S, Horowski R, Pertz HH (2005) Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 513:225–228

    Article  PubMed  CAS  Google Scholar 

  11. Junghanns S, Fuhrmann JT, Simonis G, Oehlwein Ch, Koch R, Strasser RH, Reichmann H, Storch A (2006) Valvular heart disease in Parkinson’s disease treated with dopamine agonists: A reader-blinded monocenter echocardiography study. Mov Disord (in press)

  12. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA 287:1653–1661

    Article  Google Scholar 

  13. Parkinson Study Group (2004) Levodopa and the progression of Parkinson’s disease. New Engl J Med 351:2498–2508

    Article  Google Scholar 

  14. Peralta C, Wolf E, Alber H, et al. (2006) Valvular heart disease in Parkinson’s disease vs. controls: An echocardiographic study. Mov Disord; published online

  15. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280–1286

    Article  PubMed  Google Scholar 

  16. Reichmann H, Brecht MH, Koster J, Kraus PH, Lemke MR (2003) Pramipexole in routine clinical practice: a prospective observational trial in Parkinson’s disease. CNS Drugs 17:965–973

    Article  PubMed  CAS  Google Scholar 

  17. Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ (2002) Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334–336

    Article  PubMed  Google Scholar 

  18. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D (2004) Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179–1183

    Article  PubMed  CAS  Google Scholar 

  19. Waller EA, Kaplan J, Heckman MG (2005) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 80:1016–1020

    PubMed  CAS  Google Scholar 

  20. Whone AJ, Watts RL, Stoessl AJ, Brooks DJ (2003) Slower progression of Parkinson’s disease with ropinirole versus levo-dopa. Ann Neurol 54:93–101

    Article  PubMed  CAS  Google Scholar 

  21. Yamamoto M, Uesugi T (2005) Cardiac valvulopathy in Parkinson’s disease. Mov Disord 20(Suppl 10):P317

    Google Scholar 

  22. Zadikoff C, Rochon P, Lang A (2006) Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci 33:27–33

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Neurology, University of Dresden, 01307, Dresden, Germany

    Heinz Reichmann MD, PhD

  2. Paracelsus Northsea Clinic, 27498, Helgoland, Germany

    Anja Bilsing

  3. 12163, Berlin, Germany

    Reinhard Ehret

  4. Dept. Neurology Ambrock, University Witten-Herdecke, 58091, Hagen, Germany

    Wolfgang Greulich

  5. Dept. of Neurodegeneration & Restorative Research, University of Göttingen, 37073, Göttingen, Germany

    Jörg B. Schulz

  6. Neurological Clinic, Nordstadt Krankenhaus, 30167, Hannover, Germany

    Andreas Schwartz

  7. Dept. of Clinical Pharmacology, Faculty of Medicine, 31073, Toulouse, France

    Olivier Rascol

  8. Klinik und Poliklinik für Neurologie, Universitätsklinikum Carl Gustav Carus Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany

    Heinz Reichmann MD, PhD

Authors
  1. Heinz Reichmann MD, PhD
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Anja Bilsing
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Reinhard Ehret
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Wolfgang Greulich
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Jörg B. Schulz
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Andreas Schwartz
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Olivier Rascol
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Heinz Reichmann MD, PhD.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s00415-008-0082-9.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reichmann, H., Bilsing, A., Ehret, R. et al. Ergoline and non-ergoline derivatives in the treatment of Parkinson’s disease. J Neurol 253 (Suppl 4), iv36–iv38 (2006). https://doi.org/10.1007/s00415-006-4009-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-006-4009-z

Key words